These findings, coupled with the observed efficacy of I-DXd in combination with PD-1 blockade, underscore the therapeutic potential of targeting ICAM1 in cervical cancer, particularly in TMEs characterized by high mutational burdens and suppressed immune responses [58–61]. Here, ICAM1 is linked to cervical carcinoma.